| -0.27 / -2.54%|
Endocyte, Inc. is a biopharmaceutical company, which develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Its SMDCs are actively target receptors that are over-expressed on diseased cells. The company uses companion imaging diagnostics to target the folate receptor and other target receptors, including prostate-specific membrane antigen (PSMA). Endocyte was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.
|P. Ron Ellis||President, Chief Executive Officer & Director|
|Michael A. Sherman||Chief Financial Officer|
|Philip S. Low||Director & Chief Science Officer|
|Christopher P. Leamon||Vice President-Research & Development|
|Binh Nguyen||Vice President-Clinical Affairs|